Melatonin has been proposed as a potent anti-oxidant, and its presence in many plants and foods has been suggested to be beneficial for health. Indeed, the concentrations of melatonin in blood and the melatonin metabolite 6 sulphatoxymelatonin in urine have been found to increase significantly after ingestion of melatonin-rich foods. In this review, the studies have been critically evaluated in light of the reported plant melatonin concentrations and our knowledge of pharmacokinetics of orally administered pure melatonin. In the case of studies involving measurement of plasma melatonin following ingestion of beer or fruits, the reported increase in melatonin is not consistent with the amount of melatonin ingested. Similarly, the amount of melatonin metabolite excreted following ingestion of melatonin-rich foods greatly exceeded the amount of melatonin ingested. It is concluded that studies reporting the appearance of melatonin in blood and its metabolites in urine following ingestion of melatonin-rich foods are flawed. While there may be health benefits for certain foods, it is difficult to accept that these are due to their low melatonin content.
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Pineal gland hormone; functional food; bioavailability; pharmacokinetics; antioxidant Melatonin (N-acetyl 5-methoxy tryptamine) is an indole hormone produced in the pineal gland of vertebrates from the amino acid tryptophan. In animals it appears to have many functions but the main ones revolve around the control of reproductive function in many species (Boden et al., 2013) , including its seasonality (Dardente, 2012) and facilitating the onset of sleep in humans (Keijzer et al., 2014) . A key feature of its production is that it is primarily produced and secreted during darkness, leading to it being called the "hormone of darkness." During the mid-1990s in the United States, melatonin appeared on pharmacy and supermarket shelves as a dietary supplement and there was enormous interest in and promotion of its effects as a new drug that could apparently prevent aging, cure cancer, improve your sex life, etc. (Pierpaoli and Regelson, 1995) . It is still available as a supplement in 0.5-5-mg doses in the United States, but its sale has always been restricted in other jurisdictions. When used as a dietary supplement or as a drug, it is generally taken to advance the time of sleep or assist in recovery from jet lag.
In recent years, it has emerged that melatonin is also synthesized in a wide range of plants, where physiologically it may also have a role as a hormone or as an anti-oxidant (Tan et al., 2012) . In animals, melatonin acts on membrane-bound Gprotein-coupled receptors, designated MT1 and MT2 receptors and coded by MTRN1A and MTRN1B genes (Dubocovich et al., 2010) . These are very high affinity receptors with dissociation constants in the low picomolar range.
Endogenous melatonin is metabolized in the liver by CYP1A2, sulpho-, and glucuronyl-transferase enzymes (Ma et al., 2005) to 6-hydroxymelatonin and 6-sulphatoxy melatonin (aMT.6S) or 6-glucuronyl melatonin and then excreted. It has been estimated that 90-95% of administered melatonin is excreted as these metabolites (Jones et al., 1969 ). An additional potential metabolic pathway was proposed to involve oxidation by indoleamine 2,3-dioxygenase, giving rise to N1-acetyl-N2formyl-5-methoxykynurenamine, which is then de-formylated to N1-acetyl-5-methoxykynurenamine (Hirata et al., 1974) . In vitro, this transformation can be achieved chemically or by other enzymes. Interestingly, these metabolites have not been detected in human urine following large oral doses (Li et al., 2013) . Nevertheless, melatonin has been proposed to be a potent anti-oxidant, protecting cells from reactive oxygen species damage, and there have been an extraordinary number of studies published on the potential health benefits of this role of melatonin, particularly when administered in milligram doses . In this review, the author critically evaluate the evidence that ingestion of melatonin-rich foods results in physiologically relevant amounts of melatonin being absorbed and distributed throughout the body of humans.
Melatonin in foods
Since the first report of the detection of melatonin in food (Hattori et al., 1995) , it has been measured in a very wide range of plants and plant products. In Table 1 the contents of melatonin in selected foods are listed; for more extensive lists see Paredes et al. (2009) and Huang and Mazza (2011) . It is clear that measuring melatonin in plants and foods presents important methodological issues with respect to recovery and detection of low levels of melatonin. In Table 1 , it is clear that even for the same type of food, the reported content can vary by more than 10fold between studies. In the case of cherry concentrate, one study did not detect melatonin (Kocadagli et al., 2014) , while another reported 1,420,000 pg/g (Howatson et al., 2012) . (Note that all melatonin concentrations used in this review are shown as pg/g or pg/mL to facilitate easy comparisons between studies.)
Oral administration of pure melatonin
Melatonin has been investigated over many years for its effects on sleep and temperature regulation, and consequently there have been several pharmacokinetic studies of the effects of oral administration on plasma concentrations. As summarized recently, the half-life of orally administered melatonin is less than 60 min and the volume of distribution is approximately 1000 L (Peng et al., 2013) . The bioavailability of an oral fast-release preparation has been reported to be approximately 15% (DeMuro et al., 2000; Fourtillan et al., 2000) , with men having poorer bioavailability (8.6 § 3.9%) than women (16.8 § 12.7%) (Fourtillan et al., 2000) . Using this information, we can estimate the expected plasma concentration of melatonin following oral administration. For example, assuming a volume distribution of 1000 L, we would predict that ingestion of 1000-mg melatonin would produce a blood level of approximately 1000 pg/mL. This is very close to the actual peak concentration of melatonin (1354 pg/mL) achieved 45 min after administration of 1000-mg melatonin to healthy volunteers (Dawson et al., 1996) . Using data from the other doses of melatonin administered in that study, it is clear that there is a dose response relationship between the amount administered and the subsequent peak plasma levels ( Figure 1 ; Dawson et al., 1996) . Furthermore, to increase the peak melatonin concentration by 5 pg/mL, it would require the administration of 3.5-mg (3,500,000 pg) melatonin.
Effect of "melatonin-rich" food on plasma melatonin Does the ingestion of melatonin-rich foods lead to physiologically significant changes in plasma melatonin? Maldonado et al. (2009) administered 660-mL beer containing 170-pg/mL melatonin to four men, and 330-mL beer to three women aged between 20 years and 30 years. The amount of melatonin ingested was therefore 112 ng for men and 56 ng for women. Blood was drawn before and 45 min after consumption of beer, and melatonin was assayed by ELISA.. While the actual average increase in plasma melatonin was not reported, based upon data presented in Figure 1 of the paper, it can be estimated to be approximately 2.1 pg/mL.
In another study (Sae-Teaw et al., 2013) , blood was collected from subjects before breakfast and again after ingestion of either pineapple or orange juice or whole bananas. The estimated intake of melatonin was 302, 150, and 1.7 ng for pineapple, orange, and banana respectively. Plasma melatonin analyzed by ELISA increased from 32 to 48 pg/mL, 60 min after eating the fruits to 145-151 pg/mL after 120 min and then decreased rapidly to be less than 50 pg/mL after 180 min.
Why are these results difficult to swallow? As mentioned previously, the bioavailability of melatonin is poor and the volume of distribution is approximately 1000 L. In both of the above studies, the melatonin intake was between 50 ng and 300 ng. Following absorption and distribution of oral melatonin, the maximum level that we might expect a 300-ng dose to achieve will be 300 ng/1000 L, i.e. 0.3 pg/mL, well below the reported increase. Ingestion of approximately 100 times less melatonin in the bananas curiously resulted in similar plasma melatonin profiles. Moreover, the decrease in plasma melatonin levels between 120 min and 180 min after ingestion of fruit implies a shorter half-life than has been reported previously. It is not known, what was measured in the plasma melatonin assays, but it is reasonable to suggest that it was not melatonin.
Effect of "melatonin-rich" food on melatonin metabolite excretion
Along with a potential increase in blood levels of melatonin following consumption of melatonin-rich food, it might be expected that levels of melatonin metabolites would also increase. To address this, Oba et al. (2008) altered the diet of subjects such that those on a control diet reduced the estimated melatonin intake from six selected vegetables from 133 to 5 ng per day, while those on the intervention diet, increased the Data are shown as pg/g or pg/mL. Figure 1 . Peak plasma melatonin concentration following the oral ingestion of 100-, 500-, 1000-, and 5000-mg melatonin using data from Dawson et al. (1996) . The insert shows the data between 0-and 30-mg melatonin. From this, it can be estimated that to achieve a 5-pg/mL increase in melatonin, approximately 3.5 mg would need to be consumed. estimated melatonin intake from 125 to 1288 ng per day (Oba et al., 2008) . The authors did not indicate when the vegetables were consumed or how they were prepared. Overnight first void concentrations of aMT.6S adjusted for creatinine were determined. After 65 days, aMT.6S decreased by 4.7 ng/mg creatinine in the control group (P < 0.05) and increased by 1.5 ng/mg creatinine (P > 0.05) in the intervention group. To put this in perspective, the following calculations are made. The excretion of creatinine in human urine is approximately 24 mg/kg/24 h (Greenblatt et al., 1976) , so subjects weighing 50 kg will excrete 400-mg creatinine overnight. Therefore, it can be estimated that the controls in the Oba et al. (2008) study decreased their melatonin intake by 128 ng per day, but decreased aMT.6S excretion by 1880 ng, whereas the intervention group increased their melatonin intake by 1163 ng per day and yet only increased aMT.6S by 600 ng. Nevertheless, the authors concluded that daily consumption of a high amount of selected vegetables increased concentration of aMT.6S in the first void morning urine. Jerte Valley cherries are reported to be rich in melatonin. When middle-aged and elderly subjects consumed 200 g of various cherry cultivars twice a day as lunch and dinner deserts, the aMT.6S content of overnight first void urine was increased by approximately 20-80% over baseline depending upon the cultivar (Garrido et al., 2010) . If we presume that the average excretion of aMT.6S is 30 mg per day (Fellenberg et al., 1980; Lane and Moss, 1985) , this represents an increased excretion of 6-24 mg aMT.6S per day. The cherries used in this study are reported to have a concentration of 0-22.4 ng/100 g fresh weight (Gonz alez-G omez et al., 2009), which represented a daily intake of only 0-to 90-ng melatonin.
Studies using similar protocols have been published for a Jerte Valley cherry-based product, plums, and grape juice consumed by young, middle-aged, and elderly subjects. Consumption of cherry product resulted in 1.5-, 2.4-, and 2.5-fold increase in the overnight first void aMT.6S excretion compared with baseline (Garrido et al., 2013) . Consumption of 195-g plums twice a day for five days increased overnight excretion of aMT.6S by 2-, 3-and 2-fold in young, middle-aged, and elderly participants respectively in spite of the fact that melatonin "was not quantifiable in the plums" (Gonzalez-Flores et al., 2011) . Grape juice (200 mL per day for five days) increased excretion of aMT.6S by 3-, 3-and 4-fold in the young, middle-aged, and elderly subjects respectively (Gonzalez-Flores et al., 2012) . The amount of melatonin ingested was not reported.
Montmorency cherry juice concentrate or placebo of a fruit cordial containing less than 5% fruit was ingested by subjects within 30 min of awakening and 30 minutes before the evening meal for seven days (Howatson et al., 2012) . Serial urine collections were made over 48-h periods for interventions, and aMT.6S excretion was measured. Subjects drinking cherry concentrate excreted approximately 4-mg aMT.6S compared with their baseline, while the placebo group did not change. Based upon an independent analysis of melatonin content, the concentrate apparently contained 1.42 mg/mL, which equated with a daily intake of approximately 85 mg/day.
Finally, in a follow-up study of the effects of their previous study on melatonin in fruit, urinary excretion of aMT.6S was determined following ingestion of juice or pulp from 1-kg pineapple or orange and 190-g banana after an evening meal between 1800 h and 1830 h (Johns et al., 2012) . The total urine output from 1900 h to 0700 h was collected at baseline and the night of fruit consumption. Excretion of aMT.6S increased by 180, 49, and 266% after consumption of pineapple, orange, and banana respectively. This equates to increase of approximately 54, 14.7, and 79.8 mg aMT.6S following the estimated intake of melatonin of 302, 150, and 1.7 ng for pineapple, orange, and banana respectively.
Why are these results difficult to swallow? The study by Oba et al. (2008) seriously overstated the outcome of their intervention; when the authors analyzed the positive intervention group in isolation, increasing the consumption of melatonin 10-fold by ingestion of melatonin-rich foods did not significantly increase aMT.6S excretion (Oba et al., 2008) . The studies by the University of Extramadura group (Garrido et al., 2010; Gonzalez-Flores et al., 2011; Gonzalez-Flores et al., 2012; Garrido et al., 2013) on the effects of cherries, plums, and grapes on melatonin metabolite excretion reported increase ranging from 6 to 150 mg per day. In other words, ingestion of melatonin in the order of 100 ng resulted in 60-to 1500-fold increase in metabolite excretion in the overnight first void urine. The apparent many fold increase in metabolite is probably even larger since the foods were consumed during the afternoon and evening, and the daytime ingestion would not have contributed to the observed overnight metabolite levels.
Similar assessments can be for the Montmorency cherry (Howatson et al., 2012) and pineapple, orange, and banana studies (Johns et al., 2012) . The levels of metabolite excreted do not agree with the actual melatonin intake. It should be pointed out that the concentration of melatonin reported in Montmorency cherry juice (Howatson et al., 2012) is extraordinarily high, being approximately 10,000 times higher than previously reported in any food.
The use of urinary excretion of melatonin to support the potential utility of melatonin-rich food for improving health is in itself curious. There is no question that many of those promoting the health benefits of consuming melatonin-rich foods propose that the benefits arise from the anti-oxidant properties of melatonin. For example, in a recent review it was stated that "as an antioxidant, the high levels of melatonin in plants are also beneficial to animals, including humans, who consume them. Throughout the world, billions of people depend on these products as a major food source, so the potentially beneficial effects of melatonin consumed in these products is obvious" (Tan et al., 2012) . By measuring aMT.6S excretion, the researchers are in fact determining the amount of melatonin that has escaped oxidation, and instead they are measuring melatonin metabolized by CPY1A2. It would be more useful to measure the levels of the oxidative products of melatonin such as N1-acetyl-N2-formyl-5-methoxykynurenamine and N1-acetyl-5methoxykynurenamine and/or their further metabolites or conjugates. However, as previously mentioned, these metabolites have not been detected even after ingestion of 10-mg melatonin (Li et al., 2013) .
What are the possible explanations for the detection of melatonin and its metabolites?
There are several possibilities that might explain the results that have been reported regarding the ingestion of melatonin-rich foods. The foods may contain precursors of melatonin such as tryptophan or 5-hydroxy tryptophan, which are then converted to melatonin. In a study involving the intravenous infusion of 5 gm of tryptophan over 40 min during daytime, the plasma melatonin concentration increased to 290 pg/mL, 60 min after the start of infusion and decreased to the expected low daytime levels after 5 h (Heuther et al., 1992) . In another study, subjects ingested 6 gm of tryptophan, and plasma melatonin levels increased approximately 12 pg/mL after 5 h (Christofides et al., 2006) . In the case of oral administration of 600-800-mg 5hydroxy tryptophan, plasma melatonin levels did not increase above the detection limit of 15.6 pg/mL (Cavallo et al., 1987) . It is thus unlikely that melatonin precursors are responsible for the reported increase in melatonin.
The melatonin-rich foods may contain CYP1A2 inhibitors, which delay/prevent the metabolism of endogenous melatonin, leading to elevated plasma melatonin. It is known, for example, that certain foods such as carrots, celeriac, celery, coriander, cumin, grapefruit juice, parsnip, and parsley may inhibit CYP1A2 (Perera et al., 2012) . The opposite argument would be required for studies that resulted in the many fold increase in melatonin metabolite excretion following ingestion of melatonin-rich foods. While this author is not aware of studies addressing the effects of melatonin-rich foods on CYP1A2 activity, if they did have significant activity, the overall health consequences for people taking drugs that are metabolized by CYP1A2 would be of major concern.
Finally, the assays used to measure the plasma melatonin and urinary aMT.6S levels may not be specific for their target analytes, and instead they may be detecting other interfering compounds that are perhaps related indoles, for example "melatonin isomers" Kocadagli et al., 2014) or unrelated compounds.
Conclusions
Melatonin is a remarkable compound found across plant and animals species in ng/g concentrations or lower. By virtue of studies in animals demonstrating anti-oxidant properties of endogenous and exogenous melatonin, a view has emerged that the melatonin in plants used as food may have beneficial health effects in humans. Studies reporting the appearance of melatonin in blood and its metabolites in urine following ingestion of melatonin-rich foods appear to be flawed. The known pharmacokinetic profile of melatonin following its oral administration do not support the large changes that have been reported in the literature, which in some cases represent five-fold increase in metabolite excretion over the endogenous production. While there may be health benefits of ingestion of certain foods, it is difficult to accept that they are due to their melatonin content.
